Dr. Crew on Updated Data With Margetuximab in HER2+ Breast Cancer
Katherine D. Crew, MD, MS, director of Clinical Breast Cancer Prevention Program, Columbia University Irving Medical Center, and director of DataBase Shared Resource at Herbert Irving Comprehensive Cancer Center, Columbia University, discusses updated data with margetuximab in HER2-positive breast cancer.
Katherine D. Crew, MD, MS, director of Clinical Breast Cancer Prevention Program, Columbia University Irving Medical Center, and director of DataBase Shared Resource at Herbert Irving Comprehensive Cancer Center, Columbia University, discusses updated data with margetuximab in HER2-positive breast cancer.
The phase III SOPHIA trial evaluated the monoclonal antibody margetuximab versus trastuzumab (Herceptin) in combination with investigator's choice of chemotherapy as third-line therapy in patients with metastatic HER2-positive disease. Patients had to have received 1 to 3 prior lines of therapy in the metastatic setting to be eligible for enrollment. The initial results showed modest improvements in objective response and progression-free survival, says Crew.
Data from the second interim analysis presented at the 2019 San Antonio Breast Cancer Symposium did not show a significant difference in overall survival (OS) with margetuximab. However, an exploratory analysis showed that a subset of patients with the CD16A-F allele experienced a trend toward improved OS.
